Aptevo’s Phase I APVO436 Trial on Right Track Against AML

There is good news today from the rapidly evolving field of cancer immunotherapy. Aptevo Therapeutics Inc. announced the complete remission of a patient in cohort 6 of its Phase I clinical trial of APVO436, an investigational bispecific antibody therapy being developed for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The announcement was made on the basis of preliminary data.